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ABSTRACT
Objectives The PRoposing Early Disease Indicators for 
Clinical Tracking in Fabry Disease (PREDICT- FD) initiative 
aimed to reach consensus among a panel of global experts 
on early indicators of disease progression that may justify 
FD- specific treatment initiation.
Design and setting Anonymous feedback from panellists 
via online questionnaires was analysed using a modified 
Delphi consensus technique. Questionnaires and data 
were managed by an independent administrator directed 
by two non- voting cochairs. First, possible early indicators 
of renal, cardiac and central/peripheral nervous system 
(CNS/PNS) damage, and other disease and patient- 
reported indicators assessable in routine clinical practice 
were compiled by the cochairs and administrator from 
panellists’ free- text responses. Second, the panel scored 
indicators for importance (5- point scale: 1=not important; 
5=extremely important); indicators scoring ≥3 among 
>75% of panellists were then rated for agreement 
(5- point scale: 1=strongly disagree; 5=strongly agree). 
Indicators awarded an agreement score ≥4 by >67% of 
panellists achieved consensus. Finally, any panel- proposed 
refinements to consensus indicator definitions were 
adopted if >75% of panellists agreed.
Results A panel of 21 expert clinicians from 15 countries 
provided information from which 83 possible current 
indicators of damage (kidney, 15; cardiac, 15; CNS/PNS, 
13; other, 16; patient reported, 24) were compiled. Of 45 
indicators meeting the importance criteria, consensus 
was reached for 29 and consolidated as 27 indicators 
(kidney, 6; cardiac, 10; CNS/PNS, 2; other, 6; patient 
reported, 3) including: (kidney) elevated albumin:creatinine 
ratio, histological damage, microalbuminuria; (cardiac) 
markers of early systolic/diastolic dysfunction, elevated 
serum cardiac troponin; (CNS/PNS) neuropathic pain, 
gastrointestinal symptoms suggestive of gastrointestinal 
neuropathy; (other) pain in extremities/neuropathy, 
angiokeratoma; (patient- reported) febrile crises, 
progression of symptoms/signs. Panellists revised and 
approved proposed chronologies of when the consensus 
indicators manifest. The panel response rate was >95% at 
all stages.
Conclusions PREDICT- FD captured global opinion 
regarding current clinical indicators that could prompt 
FD- specific treatment initiation earlier than is currently 
practised.
INTRODUCTION
Fabry disease (FD) affects individuals defi-
cient in lysosomal alpha- galactosidase A. The 
disease is X- linked, with an estimated preva-
lence of up to 1 in 40 000, and its multisystem 
pathology is caused by intracellular accumu-
lation of globotriaosylceramide (Gb3).1 FD 
presents with highly variable symptomatology 
ranging from patients who are asymptomatic 
to those severely affected with multiorgan 
Strengths and limitations of this study
 ► A globally representative panel of clinician- experts 
in Fabry disease (FD) was recruited.
 ► Group interaction bias was minimised by the anony-
mous consensus process.
 ► The response rate was >95% at each round of the 
consensus process.
 ► Scoring of FD indicators reflects the real- world 
views of clinicians.
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damage.1 The rate at which FD progresses also varies 
considerably.1 This poses a major challenge for physicians 
in determining prognosis, and consequently a diagnosis 
of FD does not automatically merit initiation of FD- spe-
cific treatment with enzyme replacement therapy (ERT) 
or chaperone therapy. Instead, physicians must monitor 
patients regularly to identify signs that may warrant treat-
ment initiation. The decision whether to treat may be 
complicated by the high costs of FD- specific treatments2 
and by the considerable patient burden associated with 
hospital treatment if home therapy is unavailable or inap-
propriate.3 4
In 2015, the European Fabry Working Group (EFWG) 
published consensus criteria for initiation and withdrawal 
of ERT in patients with FD.1 The general recommen-
dation applied to classically affected males and females 
and to non- classically affected males, and was to initiate 
treatment when clinical signs of kidney, heart or central 
nervous system (CNS) involvement, pain or gastrointes-
tinal symptoms first appeared.1 Treatment of classically 
affected males aged ≤16 years could also be considered in 
the absence of signs or symptoms of organ involvement, 
as could treatment of non- classically affected females with 
early clinical signs attributed to FD.1 Initiation or contin-
uation of FD- specific treatment was to be considered on 
an individual basis, and certain recommendations were 
made to withhold treatment (eg, in patients with end- 
stage renal disease with no option for renal transplant 
and advanced heart failure, or in patients with severe 
cognitive decline).1
The EFWG guidelines provide a valuable framework 
for clinical decision making in FD, but important recent 
advances in the field suggest that revising these recom-
mendations may now be appropriate. An increasing 
body of evidence supports the early initiation of ERT 
in patients with FD,5–8 and several studies show that the 
best outcomes of ERT are in patients with the least organ 
damage at treatment initiation.5 6 9–12 A study comparing 
response to FD- specific treatment after 1 year among 
treatment- naïve men starting ERT before the age of 
25 years with that among men who started treatment later, 
found a significantly greater reduction in plasma levels of 
globotriaosylsphingosine (lyso- Gb3; a marker of disease 
severity in FD) in the group treated early.13
As well as new clinical outcome data, new imaging tech-
niques such as cardiac MRI (cMRI)14 and 123I- metaiodo-
benzylguanidine single- photon emission CT15 will likely 
offer the means to detect very early FD- related organ 
damage not identified by traditional assessment methods. 
Such approaches facilitate FD- specific treatment initia-
tion before more advanced signs appear and irreversible 
organ damage occurs.
We conducted the international PRoposing Early 
Disease Indicators for Clinical Tracking in Fabry Disease 
(PREDICT- FD) modified Delphi initiative to establish 
expert consensus on early clinical indicators that may 
prompt when FD- specific treatment should be initiated 
in treatment- naïve patients. The Delphi process is a 
widely used, validated technique for developing expert 
consensus when evidence is limited and has generated 
simple, robust clinical guidance, including for the diag-
nosis and management of patients with FD.1 16–18 The 
stepwise use of questionnaires and the maintenance of 
anonymity of the experts consulted minimises data distor-
tion that can arise from the pressure on individuals within 
a group to conform to a dominant view.19 As well as exam-
ining the most relevant early clinical indicators of FD 
progression, we also aimed to gain agreement on when 
to initiate and to stop FD- specific treatment in different 
patient groups in different scenarios. The intention is that 
these findings will raise awareness among specialist and 
general physicians of the early clinical cues that should 
prompt consideration of disease- specific treatment initi-
ation in patients with FD, so that disease progression and 
irreversible organ damage in these patients is minimised 
or avoided.
METHODS
The modified Delphi process used in PREDICT- FD is 
described below and summarised in figure 1.
Selection of chairs and expert panel
Two leading global experts in FD were invited to be 
non- voting cochairs of the PREDICT- FD initiative. The 
cochairs selected an international group of FD experts to 
form the voting panel. Panel members were nominated 
based on track record and demonstrated expertise in 
the field, according to factors such as research activities, 
participation in national or regional FD management 
initiatives and authorship of relevant peer- reviewed publi-
cations. Nominated panellists were recruited on behalf 
of the initiative cochairs by an independent third- party 
administrator (Oxford PharmaGenesis, Oxford, UK).
Modified Delphi process
Under the direction of the PREDICT- FD cochairs, the 
third- party administrator drafted a study protocol, which 
was reviewed and approved by both cochairs and by a 
patient representative before commencement of the 
initiative. A non- exhaustive literature search was also 
conducted by the administrator for the cochairs and was 
used to inform aspects of the initiative (see online supple-
mentary appendix). All stages of the initiative, including 
content development, data collation, data processing and 
reporting, were overseen by the cochairs and conducted 
by the independent third- party administrator. Expert 
panel responses were gathered anonymously via an online 
survey platform (SurveyMonkey, SurveyMonkey Europe, 
Dublin, Ireland). For tracking purposes, the adminis-
trator knew the identities of responding panellists, but no 
identifying information was shared with the cochairs or 
other panel members. Panellists remained anonymous to 
each other throughout the Delphi stages. Circulation of 
the questionnaires, and collection and processing of the 
panel’s responses was conducted between January and 
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September 2018. Except for comment fields included in 
the questionnaires, all questions were compulsory. No 
controlled feedback was provided to panellists between 
rounds.
Further details on the design of the modified Delphi 
initiative, including all questionnaires, are provided in 
the online supplementary appendix. Achieving consensus 
with three rounds of questionnaires was planned. In 
round 1, information was solicited regarding panellists’ 
FD clinical practices, number of years spent treating 
patients with FD and number of patients with FD typically 
managed in their practices. Panellists provided free- text 
responses to open questions soliciting suggestions for 
early indicators of renal, cardiac and CNS damage that 
can be assessed in current routine clinical practice, or 
that are not assessed routinely at present, but might be 
in the future. Additional round 1 questions explored 
symptoms experienced by patients with FD that could 
contribute to initiating FD- specific treatment. Attitudes 
towards FD- specific treatment initiation or cessation 
were also investigated by asking panellists to rate on an 
11- point scale (0=not at all likely; 10=extremely likely) the 
likelihood that they would start or stop FD- specific treat-
ment in different patient groups and clinical scenarios 
proposed by the cochairs.
Among questions in round 1 that solicited free- text 
responses, the administrator identified similar themes 
among the responses and created provisional groupings 
for review by the cochairs. The cochairs checked and 
revised the groupings to exclude indicators that are not 
widely used, are known to be of greater relevance in late- 
stage than in early- stage disease or are poorly indicative of 
FD status and progression. The administrator generated 
lists of indicators and compiled responses from the panel 
regarding attitudes to FD- specific treatment initiation or 
cessation in different patient groups, determining the 
panel’s median likelihood scores for starting or stopping 
FD- specific treatment.
In round 2, panellists rated the importance of each 
indicator on a 5- point Likert scale (1=not important; 
2=slightly important; 3=important; 4=very important; 
5=extremely important). Regarding scenarios for 
initiation or cessation of FD- specific treatment, if a 
scenario was awarded a median likelihood score of ≥7.5 
in round 1, agreement was sought whether to start or 
Figure 1 PREDICT- FD modified Delphi consensus methodology. aA threshold median likelihood score of 7.5 was set a priori. 
For questions about the likelihood of initiating treatment, agreement for initiation was sought in round 2 if a scenario was 
awarded a median score of ≥7.5 and agreement not to initiate treatment sought if the score was <7.5. Similarly, for questions 
about cessation of treatment, agreement to stop treatment was sought in round 2 if a scenario was awarded a median score 
≥7.5 and agreement not to stop treatment sought if the score was <7.5. PREDICT- FD, PRoposing Early Disease Indicators for 
Clinical Tracking in Fabry Disease.
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to stop FD- specific treatment. In contrast, if the score 
was <7.5, agreement was sought whether to start or to 
stop treatment. Panellists rated their level of agree-
ment using a 5- point Likert scale (1=strongly disagree; 
2=disagree; 3=neither agree nor disagree; 4=agree; 
5=strongly agree). Importance and agreement ratings 
were compiled by the administrator. It was specified a 
priori that indicators awarded an importance score of 
≥3 by >75% of the panel would be tested for consensus 
in round 3, and that agreement on treatment recom-
mendations would be reached if an agreement score 
of ≥4 was awarded by >67% of the panel. All ratings 
compiled by the administrator were reviewed by the 
cochairs as per the predefined scores and consistent 
with previous Delphi initiatives20 21; agreement on 
treatment recommendations concluded in round 2. In 
round 3, panellists rated their level of agreement with 
each indicator that had met the designated impor-
tance criteria in round 2, using the 5- point Likert scale 
already described. Consensus was established using 
the same a priori criteria already described. Agree-
ment scores were compiled by the administrator and 
reviewed by the cochairs.
Round 4 was included post hoc to capture the panel’s 
level of agreement with certain indicators that met the 
importance criteria in round 2 but which were inadver-
tently omitted from round 3. Panel members were also 
asked whether they agreed or disagreed with refine-
ments proposed for several indicators that achieved 
consensus in round 3 and these were adopted if >75% 
of the panel agreed; refinements were informed by 
comments made by panel members during the first 
three rounds. Panellists’ responses were compiled by 
the administrator, reviewed by the cochairs, and any 
new consensus terms combined with those identified 
in round 3.
Chronology of signs and symptoms
After generating the refined list of consensus indicators, 
timelines were developed under the direction of the 
cochairs showing when each indicator typically mani-
fests during the disease course in relation to established 
indicators currently recommended as triggers for treat-
ment initiation. Indicators manifesting before and after 
established indicators were termed ‘early’ and ‘late’, 
respectively. Indicators featuring in the chronologies 
were grouped as renal, cardiac or patient reported/
other. The cochairs agreed a draft chronology for each 
group, and these proposals were submitted to each 
panel member for comment and amendment. Panel 
responses were collated, and the chronologies revised 
by the administrator then approved by the cochairs. 
The chronologies were developed between December 
2018 and January 2019; Delphi consensus techniques 
were not applied to this part of the initiative.
Statistical analyses
The study was exploratory; no hypotheses were tested and 
only descriptive statistical analyses were performed.
Patient and public involvement statement
A leadership representative from the Fabry Interna-
tional Network (FIN), JJ, was invited to participate in 
the project in a non- voting role. The representative 
reviewed and approved the initial protocol and round 
1 questionnaire, and facilitated the involvement of 
three patients with FD (one from the USA and two 
from outside the USA) in reviewing these materials. 
This ensured that any appropriate feedback from the 
patients could be incorporated into materials before 
distributing the round 1 questionnaire. Additional 
roles of the FIN representative included capturing 
these patients’ views on the outcomes of the initiative, 
and reviewing and approving the final study report.
RESULTS
PREDICT-FD expert panel demographics and clinical 
experience
In total, 23 experts were invited to join the expert panel; 
one declined to participate, and one did not complete 
round 1 and was excluded from the analysis. Thus, the 
panel comprised 21 physicians representing 15 countries 
(Argentina, Australia, Canada, Czech Republic, France, 
Italy, Norway, Portugal, Slovenia, Spain, Switzerland, 
Taiwan, Turkey, UK, USA). All panellists had managed 
male and female patients with FD; most panellists had 
experience of managing both patients with classical and 
those with non- classical FD (table 1).
The majority of panellists (18 (85.7%)) practised in 
public teaching hospitals. Panellists had treated patients 
with FD for a mean of 15.5 years and four panellists 
(19.0%) had >20 years of clinical experience with FD. 
Specialties most commonly represented were nephrology 
(8 (38.1%)), metabolic diseases (5 (23.8%), of whom 3 
(14.3%) also specialised in genetics) and cardiology (4 
(19.0%)); haematology, immunology, neurology, paedi-
atrics, internal medicine, biochemistry and angiology 
were also represented. Overall, the panel managed an 
estimated 2079 patients, 40.7% of whom were male; 
64.5% of patients had classical FD (table 1). A response 
rate of 95.5% (21/22) was achieved during round 1 of 
the modified Delphi process; thereafter all 21 panellists 
responded.
Consensus on current and potential future indicators of 
disease progression in FD
Indicators achieving consensus in round 3 of the modi-
fied Delphi process were further refined in round 4 (see 
section ‘Refinements to consensus indicators’ for further 
information); the final list of consensus indicators is 
summarised in table 2. Results by organ system and cate-
gory are described below.
Indicators of renal damage
Following consolidation by the cochairs, 15 indicators of 
early renal damage in current use and 19 potential future 
indicators were collated from round 1. Of these, seven 
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current and two future indicators met the predefined 
importance criteria in round 2. Consensus was reached 
for the following current indicators (see online supple-
mentary table S1): elevated urine albumin:creatinine 
ratio; histological damage (lesions associated with Gb3 
deposition); microalbuminuria; abnormal glomerular 
filtration rate (GFR); decline in iohexol GFR and podo-
cyte inclusions in renal biopsies. Consensus was not 
achieved for any future indicators.
Indicators of cardiac damage
After consolidation at the end of round 1, 15 current and 
14 future indicators of early cardiac damage were iden-
tified, and 12 current and 3 future indicators met the 
importance criteria in round 2. Consensus was reached for 
10 current indicators, 3 of which also reached consensus 
as future indicators (see online supplementary table S2). 
The indicators deemed important, both currently and 
in the future, were: reduced myocardial T1 relaxation 
time on cMRI; elevated serum cardiac troponin; and 
elevated serum N- terminal probrain natriuretic peptide 
(NT- pro- BNP). The other important current indicators 
were: markers of early systolic/diastolic dysfunction; early 
indicators of left ventricular hypertrophy (LVH); histo-
logical damage (lesions associated with Gb3 deposition) 
in endomyocardial biopsies; late gadolinium enhance-
ment on cMRI; abnormal ECG; abnormal echocardio-
gram; and, specifically, abnormal wall motion revealed by 
echocardiogram.
Indicators of peripheral nervous system damage
In round 1 following consolidation, 13 current and 13 
future indicators were identified, with 5 and 2 indica-
tors, respectively, subsequently meeting the importance 
criteria in round 2 (see online supplementary table S3). 
Consensus was reached for neuropathic pain and gastro-
intestinal symptoms suggestive of gastrointestinal neurop-
athy as current indicators; no consensus was achieved for 
future indicators.
Other indicators
When asked for further information about early indi-
cators of FD, such as non- organ- specific symptoms, 
consensus was reached for five indicators (see online 
supplementary table S4): pain in extremities/neurop-
athy; angiokeratoma; organ biopsy (including skin biopsy 
for small- fibre neuropathy); gastrointestinal symptoms 
(including bloating, pain, diarrhoea/frequent diarrhoea 
or constipation); and sweating abnormalities or heat/
exercise intolerance.
Patient-reported indicators
Panellists were asked to list what they considered to be 
the earliest signs and symptoms relevant to FD progres-
sion and FD- specific treatment initiation, and also to list 
patient- reported signs and symptoms relevant to FD- spe-
cific treatment initiation. When the responses were 
combined, consensus was achieved for the following six 
patient- reported indicators: stroke/transient ischaemic 
attack; febrile crises; patient- reported progression of 
symptoms/signs of FD (such as acral burning paraes-
thesias, heat intolerance, impaired sweating, fatigue, 
depression, pain, gastrointestinal symptoms, shortness 
of breath, palpitations, peripheral oedemas); diarrhoea/
frequent diarrhoea; angiokeratoma; and neuro- otological 
abnormalities (see online supplementary table S5). 
Based on consensus reached in round 4, stroke/tran-
sient ischaemic attack and diarrhoea/frequent diarrhoea 
were reclassified among ‘other indicators’, and neuro- 
otological abnormalities was discarded (see ‘Refinements 
to consensus indicators’).
Indicators under research
Of the eight indicators that were the focus of experimental 
studies or ongoing research, five were deemed important, 
and two achieved consensus (see online supplementary 
table S6): reduced quality of life and high gastrointestinal 
symptom scores.
Table 1 PREDICT- FD modified Delphi expert panel clinical 
experience
Clinical experience (n=21)
Main clinical practice*
  Private teaching hospital 1 (4.8)
  Private hospital 0
  Public teaching hospital 18 (87.5)
  Public non- teaching hospital 0
  Research centre 6 (28.6)
Duration of FD clinical experience, years
  Mean (SD) 15.5 (7.5)
  0–10 6 (28.6)
  11–20 11 (52.4)
  21–30 4 (19.0)
Number of patients with FD managed
  Mean (SD) 99 (81)
  1–50 4 (19.0)
  51–100 12 (57.1)
  101–200 3 (14.3)
  >200 2 (9.5)
Patient summary†
  Male 847 (40.7)
  Female 1232 (59.3)
  Classical FD 1341 (64.5)
  Non- classical FD 738 (35.5)
Data are shown as number (%) of respondents unless otherwise 
stated.
*Respondents could select more than one option.
†Patient n (%) values are estimates, derived from total patient 
numbers and estimated sex and FD- type breakdown reported by 
each panellist.
FD, Fabry disease; PREDICT- FD, PRoposing Early Disease 
Indicators for Clinical Tracking in Fabry Disease.
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Refinements to consensus indicators
During the first three rounds, panellists offered addi-
tional information about the indicators, typically to 
define broad indicators more precisely. Comments on the 
current indicators that achieved consensus were reviewed 
by the cochairs, and proposed clarification on 23 of these 
was circulated to the panel in round 4, either to endorse 
new information or to provide an opportunity to include 
additional information. The panel reached agreement on 
refinements to 19 of these indicators (see online supple-
mentary table S7; ‘neuro- otological abnormalities’ was 
excluded from the consensus because it encompassed 
the other indicators ‘vertigo’, ‘hearing loss’ and ‘tinnitus’ 
that had not achieved consensus (see online supple-
mentary tables S4,S5). The current and potential future 
indicators, as well as those under research, that achieved 
final consensus are summarised in table 2; explanatory 
table footnotes describe the refinements made in round 
4 based on feedback from the panel.
Chronology of manifestation of indicators during the disease 
course
Indicators that achieved consensus were allocated to 
three groups: renal; cardiac; and patient reported/
other, and a chronology was developed for each group 
(figure 2A–C).
Initiation and cessation of FD-specific treatment in patients 
with FD
In round 1, the panel rated the likelihood of initiating 
FD- specific treatment in different scenarios (patients 
asymptomatic for organ damage, symptomatic patients 
not meeting guideline criteria, patients meeting guide-
line criteria) in five different patient groups (defined 
by sex, age group, and classical or non- classical FD) (see 
online supplementary figure S1A). The panel’s level of 
agreement in round 2 with proposals that treatment 
should or should not be started in different patient 
groups in different scenarios is summarised in table 3. 
Agreement was reached in round 2 that FD- specific 
treatment should be initiated in all males aged ≥16 years 
with classical disease, and in males of any age with clas-
sical disease and with early indicators of organ damage, 
irrespective of whether these symptoms meet the EFWG 
recommendations for treatment initiation.1 Agreement 
that FD- specific treatment should be initiated was also 
reached for all female patients and for male patients with 
non- classical disease with indicators meeting the EFWG 
guideline criteria.1 Agreement not to start treatment was 
reached only for asymptomatic females with non- classical 
FD (table 3). However, when asked if all patients who 
meet the EFWG guideline criteria1 should receive FD- spe-
cific treatment, the panel did not reach agreement (mean 
(median) score, 3.4 (4); score ≥4, 11 (52.4%)), including 
for female patients with classical FD and male patients 
with non- classical FD.
The panel’s responses regarding starting or stopping 
FD- specific treatment in scenarios relating to organ 
damage are summarised in table 4 and online supplemen-
tary figure S1B. Agreement was reached that treatment 
should be initiated in patients with evidence of damage to 
a single organ system, irrespective of whether that organ 
system was being treated by a non- Fabry- specific interven-
tion (eg, renal replacement therapy, kidney transplant or 
cardiac pacemaker, etc), and that FD- specific treatment of 
such patients should not be stopped, were such a therapy 
to become necessary. Agreement was also reached that 
FD- specific treatment should be initiated and should not 
be stopped in patients receiving separate therapies for 
damage to multiple organ systems (such as a combination 
of renal replacement therapy, kidney transplant and/or 
cardiac pacemaker, etc). The group in which the panel 
was least likely to initiate or to stop FD- specific treatment 
was that comprising patients who were receiving no sepa-
rate therapy for multiple organ system damage. However, 
no agreement was reached for either scenario. The panel 
also did not reach agreement on the question of whether 
all patients with FD should remain on disease- specific 
treatment, irrespective of organ damage or any related 
treatment (mean (median) agreement score, 2.2 (2); 
agreement score ≥4, 6 (28.6%)).
DISCUSSION
The PREDICT- FD panel was convened to identify early 
clinical indicators that could prompt disease- specific treat-
ment initiation in patients with FD, thereby minimising 
disease progression. The panel reached consensus on 27 
early renal, cardiac, peripheral nervous system (PNS), 
patient- reported and other indicators of disease progres-
sion that can currently be assessed in FD clinics (table 2). 
Other indicators that were considered important but 
where no consensus was reached or that were categorised 
as being of no importance, are summarised in the supple-
mentary tables. Three indicators of cardiac damage 
were also identified that might be adopted more widely 
for routine use in future and the utility of two other 
consensus indicators are the focus of ongoing research. 
In the opinion of the panellists, treatment should be initi-
ated in any male patients with classical FD aged at least 
16 years, and in younger males with classical disease if 
early signs of organ damage appear. Female patients and 
male patients with non- classical disease should be treated 
based on existing guideline recommendations.
Detection of renal histological damage requires a 
biopsy, which is highly invasive, so the presence of other, 
less invasive early indicators could be sufficient grounds 
to start FD- specific treatment without biopsy data. The 
panel reached a consensus that early indicators of renal 
damage included microalbuminuria, glomerular hyper-
filtration and podocyte inclusions in the presence of 
other renal lesions, such as signs of glomerulosclerosis or 
vasculopathy, which may occur even in patients without 
microalbuminuria (figure 2).22 23
Regarding cardiac indicators, consensus was reached on 
several early indicators of cardiac damage, including ECG 
8 Hughes DA, et al. BMJ Open 2020;10:e035182. doi:10.1136/bmjopen-2019-035182
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abnormalities (eg, shortened PR interval) elevated cardiac 
troponin, elevated NT- pro- BNP and low myocardial T1 
relaxation times on cMRI, although the utility of the last 
may be limited by the low availability of T1 mapping by 
cMRI in specialist FD centres. Grade 1 diastolic dysfunc-
tion in early FD24 may be a useful indicator of cardiac 
changes, but perhaps only in young patients. Because LVH 
is an established sign of cardiac involvement in FD, any 
tests revealing early stages of hypertrophy could be valu-
able in informing treatment decisions and could help to 
slow cardiac disease progression on treatment.25 Elevated 
high- sensitivity cardiac troponin and NT- pro- BNP levels 
are early signs of cardiac damage that might be detect-
able before signs that can be seen with cMRI. A concern 
Figure 2 Chronology of consensus indicators. (A) *Indicator tested for, but not achieving, consensus in round 3. (B) †Indicators 
in red text achieved consensus both as currently used, and suitable for future adoption, because they are not available in all 
centres. Two further indicators (abnormal PET/MRI and increased serum lyso Gb3) that were included in round 2 of the initiative 
but were not taken forward to round 3 are not shown here based on guidance from the cochairs. (C) *Indicator tested for, but 
not achieving, consensus in round 3. Other indicators tested for, but not achieving, consensus, and which are not included here 
owing to their lack of specificity were: biomarkers; patient- reported outcomes; absenteeism owing to ill health; and palpitations. 
aIndicators that currently would be likely to trigger FD- specific treatment initiation. bIn isolation, probably insufficient justification 
for FD- specific treatment initiation. cMicroalbuminuria could be a trigger for further investigation, such as confirmatory biopsy, 
and subsequent initiation of disease- specific treatment. dIncluding decreased myocardial strain and strain rate, tissue Doppler 
abnormalities, enlarged left atrium, abnormal wall motion or pulmonary vein abnormalities. eIncluding shortened PR interval, 
non- SVT and symptomatic bradycardia. ACR, albumin:creatinine ratio; AF, atrial fibrillation; FD, Fabry disease; GFR, glomerular 
filtration rate; LGE, late gadolinium enhancement; LVH, left ventricular hypertrophy; lyso Gb3, globotriaosylsphingosine; NT- pro- 
BNP, N- terminal probrain natriuretic peptide; PET, positron emission tomography; SVT, sustained VT; VT, ventricular tachycardia.
9Hughes DA, et al. BMJ Open 2020;10:e035182. doi:10.1136/bmjopen-2019-035182
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raised by panellists was that later manifestations of cardiac 
damage do not typically respond to FD- specific treatment. 
Histological markers have the potential to reveal very early 
cardiac tissue changes, but undertaking a cardiac biopsy is 
too invasive to be recommended as a routine screen for FD 
progression.
Other clinical and patient- reported early indicators of 
FD, such as neuropathic pain, gastroenterological symp-
toms and difficulties with hearing or balance, are well- 
known signs and symptoms experienced by patients with 
FD. Such clinical features could contribute to a physi-
cian’s decision to treat but may respond only partially to 
FD- specific treatment.
Implications of the consensus indicators for the start of 
treatment
The panel reached a consensus on initiating FD- specific 
treatment in predefined patient groups. In particular, 
the panel agreed that treatment should be initiated for 
all males ≥16 years of age with the classical FD mutation 
regardless of symptom status. Similarly, the panel agreed 
that treatment should be initiated among males <16 years 
of age with classical FD demonstrating early or guideline- 
associated indicators. However, there was no consensus 
on initiating treatment in asymptomatic males <16 years 
of age. In particular, consensus regarding early renal and 
cardiac indicators of disease progression could encourage 
FD centres to monitor for these indicators, pre- empting 
accrual of irreversible organ damage. Furthermore, 
agreement among the panel about the most suitable 
patient groups for FD- specific treatment initiation indi-
cates that the current guideline recommendations1 could 
be updated, and the impact of early intervention could 
be audited for beneficial outcomes. Likewise, policy- 
makers can use observational and longitudinal data to 
examine the cost–benefit implications of early treatment 
of patients for avoidable complications, as well as appro-
priate cessation of therapy in specific patient groups.
Results of the PREDICT-FD initiative in context
The PREDICT- FD modified Delphi initiative represents 
the broadest evaluation of early indicators of FD- spe-
cific treatment initiation to date. Previous Delphi initia-
tives have evaluated indicators specific to renal or cardiac 
organ damage,17 18 with a focus on tissue biopsy evaluation. 
However, biopsies are invasive and other approaches are 
available to aid early identification of disease progression. 
The use of biopsies in the diagnosis of FD was also key in a 
Delphi initiative exploring diagnosis, treatment and adverse 
event management.16 This Delphi panel reached conclu-
sions similar to those of the PREDICT- FD panel regarding 
initiation of treatment.16 Both the cardiac and renal Delphi 
panels recognised serum lyso Gb3 levels as a potential indi-
cator, although it might have limited specificity in kidney 
damage.17 18 Lyso Gb3 has also been proposed as a poten-
tial primary biomarker for FD in other studies.26 27 In the 
PREDICT- FD panel, there was no consensus on the use of 
lyso Gb3 as an early indicator of organ damage or treatment T
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initiation, with the strongest marker of the importance of 
lyso Gb3 observed for cardiac damage.
Strengths and weaknesses of the PREDICT-FD modified Delphi 
initiative
The anonymised nature of Delphi methodology should 
minimise the possibility of bias often seen in face- to- face 
group interactions, thereby strengthening the validity of the 
consensus process. However, clinicians in a relatively small 
and highly specialised field may well be aware of the opin-
ions of their peers, which may have influenced the responses 
provided in our study. With this qualification, the anonymity 
of the panellists was maintained until the Delphi stages 
were complete and the disease chronologies circulated 
for comment. Furthermore, the overall response rate was 
>95%, indicating that panellists’ knowledge and opinions 
were well represented. However, because the importance- 
and agreement- rating steps in this Delphi consensus were 
opinion based, it is possible that a different consensus would 
have been reached, had the panel comprised different 
medical specialties. Thus, the generalisability of our findings 
is influenced by the panel composition and by the degree 
to which each panellist’s perspective represents that of FD 
specialists not polled. Such shortcomings are implicit in the 
Delphi process and the findings require further evaluation 
in real- world clinical practice to confirm their relevance. 
Weaknesses of the methodology were the absence of a 
neutral response option for those unfamiliar with the rele-
vance of an indicator during the importance rating stage, 
and that no controlled feedback was provided to panellists 
between rounds. Another was that no attempt was made to 
achieve consensus on the utility of indicators that did not 
meet the consensus criteria. Conceivably, this would have 
led to some indicators being completely discounted, leaving 
others whose utility remains to be proven.
Conclusion and implications for future research
The PREDICT- FD modified Delphi initiative achieved 
consensus on 27 early renal, cardiac, PNS, patient- reported 
and other indicators of disease progression that could 
prompt FD- specific treatment initiation earlier than is 
currently practised. These findings should raise awareness 
among physicians of the early clinical cues that should 
prompt consideration of disease- specific treatment initia-
tion in FD, so that disease progression and irreversible organ 
damage in these patients is minimised or avoided. Empiri-
cally, early treatment is associated with better outcomes 
than delaying treatment of FD, but there is currently scant 
information about the responsiveness to treatment of many 
of the early indicators of disease progression identified in 
PREDICT- FD. Further evidence is needed to understand 
the latest stage at which treatment can be initiated to mini-
mise the long- term complications of FD.
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